Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its first variants in fourplex real-time quantitative reverse transcription-PCR assays.

Mathieu Durand\textsuperscript{2}, Philippe Thibault\textsuperscript{2}, Simon Lévesque\textsuperscript{3,4}, Ariane Brault\textsuperscript{1}, Alex Carignan\textsuperscript{3}, Louis Valiquette\textsuperscript{3}, Philippe Martin\textsuperscript{3}, and Simon Labbé\textsuperscript{1}*  

\textsuperscript{1}Département de Biochimie et de Génomique Fonctionnelle, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada.  
\textsuperscript{2}Plateforme RNomique et de Génomique Fonctionnelle, Université de Sherbrooke, Sherbrooke, QC, Canada.  
\textsuperscript{3}Département de Microbiologie et d’Infectiologie, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada.  
\textsuperscript{4}Laboratoire de Microbiologie, Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l’Estrie, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, J1H 5N4, Canada.

*Corresponding author : Simon Labbé  
E-mail: Simon.Labbe@USherbrooke.ca

TABLE OF CONTENT : Supplemental Figure 1.

Legend

\textbf{Fig. S1.} \emph{Sequences of the synthetic oligomers used to create the indicated gBlocks.} Each targeted SARS-CoV-2 region from the Orf1ab, Spike, E (envelope), and N (nucleocapsid) genes (according to the Wuhan-Hu-1 genome reference sequence and mutant derivatives) were designed accompanied with a T7 promoter sequence (bold) at their 5’ends.
Supplemental Figure 1. Sets of oligonucleotide primers

Orflab forward and reverse (strain L)

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

Orflab forward and reverse (strain S)

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

Spike D614 forward and reverse

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

Spike 614G forward and reverse

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

Spike N501 forward and reverse

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

Spike S01Y forward and reverse

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

E Sarbeco forward and reverse

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

N LSQ forward and reverse

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

B2M exons 2-3 forward and reverse

5'-TAATAGACTACCTACTAGGAGTTGTTGTCATCTGTGACATAGCATCAGATACCTTGTTTGGCTAAACAAATGCGATTTTGGCAACACATGTTGAGCC
AGCTGCTGCTTATGATTGAAATCTACTGACAAAGCTGCGGAGAAGCTTGGTTCGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT
ACCCAGGCTGAGTTTGGCTGAGTTGCTGATAAATACCCAGGCTGATTTCTGCTCTTAAT

Bold sequences indicate primer sets used for RNA synthesis.